Peroxiredoxin3 (Prdx3) is an intracellular antioxidant enzyme that is specifically localized in mitochondria and protects against oxidative stress by removing mitochondrial reactive oxygen species (ROS). The intestinal epithelium provides a physical and biochemical barrier that segregates host tissues from commensal bacteria to maintain intestinal homeostasis. An imbalance between the cellular antioxidant defense system and oxidative stress has been implicated in the pathogenesis of inflammatory bowel disease (IBD). However, the role of Prdx3 in the intestinal epithelium under intestinal inflammation has not been elucidated. To investigate the potential role of Prdx3 in intestinal inflammation, we used intestinal epithelial cell (IEC)-specific Prdx3-knockout mice.
Results:
IEC-specific Prdx3-deficient mice showed more severe colitis phenotypes with greater degrees of body weight loss, colon shortening, barrier disruption, mitochondrial damage, and ROS generation in IECs. Furthermore, exosomal miR-1260b was dramatically increased in Prdx3-knockdown colonic epithelial cells. Mechanistically, Prdx3 deficiency promoted intestinal barrier disruption and inflammation via P38-mitogen-activated protein kinase/NFκB signaling.
Innovation:
This is the first study to report the protective role of Prdx3 in acute colitis using IEC-specific conditional knockout mice.
Conclusion:
Our study sheds light on the role of exosome-loaded miRNAs, particularly miR-1260b, in IBD. Targeting miR-1260b or modulating exosome-mediated intercellular communication may hold promise as potential therapeutic strategies for managing IBD and restoring intestinal barrier integrity. Antioxid. Redox Signal. 42, 133–149.
Get full access to this article
View all access options for this article.
References
1.
Al-SadiR, EngersJ, AbdulqadirR. Talk about micromanaging! Role of microRNAs in intestinal barrier function. Am J Physiol Gastrointest Liver Physiol, 2020; 319(2):G170–G174; doi: 10.1152/ajpgi.00214.2020
2.
Al-SadiR, GuoS, YeD, et al.Mechanism of IL-1β modulation of intestinal epithelial barrier involves p38 kinase and activating transcription factor-2 activation. J Immunol, 2013; 190(12):6596–6606; doi: 10.4049/jimmunol.1201876
3.
Al-SadiR, YeD, SaidHM, et al.IL-1beta-induced increase in intestinal epithelial tight junction permeability is mediated by MEKK-1 activation of canonical NF-kappaB pathway. Am J Pathol, 2010; 177(5):2310–2322; doi: 10.2353/ajpath.2010.100371
4.
BelchevaA. MicroRNAs at the epicenter of intestinal homeostasis. Bioessays, 2017; 39(3); doi: 10.1002/bies.201600200
5.
BergerE, RathE, YuanD, et al.Mitochondrial function controls intestinal epithelial stemness and proliferation. Nat Commun, 2016; 7:13171; doi: 10.1038/ncomms13171
BushatiN, CohenSM. microRNA functions. Annu Rev Cell Dev Biol, 2007; 23:175–205; doi: 10.1146/annurev.cellbio.23.090506.123406
9.
ChangTS, ChoCS, ParkS, et al.Peroxiredoxin III, a mitochondrion-specific peroxidase, regulates apoptotic signaling by mitochondria. J Biol Chem, 2004; 279(40):41975–41984; doi: 10.1074/jbc.M407707200
10.
ChenH. microRNA-based cancer diagnosis and therapy. Int J Mol Sci, 2023; 25(1):230; doi: 10.3390/ijms25010230
11.
ChiaradiaE, TanciniB, EmilianiC, et al.Extracellular vesicles under oxidative stress conditions: Biological properties and physiological roles. Cells, 2021; 10(7):1763; doi: 10.3390/cells10071763
12.
DamianiCR, BenettonCA, StoffelC, et al.Oxidative stress and metabolism in animal model of colitis induced by dextran sulfate sodium. J of Gastro and Hepatol, 2007; 22(11):1846–1851; doi: 10.1111/j.1440-1746.2007.04890.x
13.
DelpreG, AvidorI, SteinherzR, et al.Ultrastructural abnormalities in endoscopically and histologically normal and involved colon in ulcerative colitis. Am J Gastroenterol, 1989; 84(9):1038–1046.
14.
Di MambroT, PellieloG, AgyapongED, et al.The Tricky Connection between Extracellular Vesicles and Mitochondria in Inflammatory-Related Diseases. Int J Mol Sci, 2023; 24(9):8181; doi: 10.3390/ijms24098181
15.
GajendranM, LoganathanP, JimenezG, et al.A comprehensive review and update on ulcerative colitis. Dis Mon, 2019; 65(12):100851; doi: 10.1016/j.disamonth.2019.02.004
16.
GentlemanRC, CareyVJ, BatesDM, et al.Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol, 2004; 5(10):R80; doi: 10.1186/gb-2004-5-10-r80
17.
HabermanY, KarnsR, DexheimerPJ, et al.Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response. Nat Commun, 2019; 10(1):38; doi: 10.1038/s41467-018-07841-3
18.
HerrmannIK, WoodMJA, FuhrmannG. Extracellular vesicles as a next-generation drug delivery platform. Nat Nanotechnol, 2021; 16(7):748–759; doi: 10.1038/s41565-021-00931-2
19.
HirataH, HinodaY, ShahryariV, et al.Genistein downregulates onco-miR-1260b and upregulates sFRP1 and Smad4 via demethylation and histone modification in prostate cancer cells. Br J Cancer, 2014; 110(6):1645–1654; doi: 10.1038/bjc.2014.48
20.
HirataH, UenoK, NakajimaK, et al.Genistein downregulates onco-miR-1260b and inhibits Wnt-signalling in renal cancer cells. Br J Cancer, 2013; 108(10):2070–2078; doi: 10.1038/bjc.2013.173
21.
HoGT, TheissAL. Mitochondria and Inflammatory Bowel Diseases: Toward a Stratified Therapeutic Intervention. Annu Rev Physiol, 2022; 84:435–459; doi: 10.1146/annurev-physiol-060821-083306
22.
HorieK, MikamiT, YoshidaT, et al.Peroxiredoxin 1 expression in active ulcerative colitis mucosa identified by proteome analysis and involvement of thioredoxin based on immunohistochemistry. Oncol Lett, 2018; 15(2):2364–2372; doi: 10.3892/ol.2017.7549
23.
HsiehSY, ShihTC, YehCY, et al.Comparative proteomic studies on the pathogenesis of human ulcerative colitis. Proteomics, 2006; 6(19):5322–5331; doi: 10.1002/pmic.200500541
24.
HuangZ, ZhenS, JinL, et al.miRNA-1260b Promotes Breast Cancer Cell Migration and Invasion by Downregulating CCDC134. Curr Gene Ther, 2023; 23(1):60–71; doi: 10.2174/1566523222666220901112314
25.
HwangJ, JinJ, JeonS, et al.SOD1 suppresses pro-inflammatory immune responses by protecting against oxidative stress in colitis. Redox Biol, 2020; 37:101760; doi: 10.1016/j.redox.2020.101760
26.
JacksonDN, PanopoulosM, NeumannWL, et al.Mitochondrial dysfunction during loss of prohibitin 1 triggers Paneth cell defects and ileitis. Gut, 2020; 69(11):1928–1938; doi: 10.1136/gutjnl-2019-319523
27.
JungH, KimJS, LeeKH, et al.Roles of microRNAs in inflammatory bowel disease. Int J Biol Sci, 2021; 17(8):2112–2123; doi: 10.7150/ijbs.59904
28.
KimT, CroceCM. MicroRNA: Trends in clinical trials of cancer diagnosis and therapy strategies. Exp Mol Med, 2023; 55(7):1314–1321; doi: 10.1038/s12276-023-01050-9
29.
KimDH, ParkH, ChoiYJ, et al.Exosomal miR-1260b derived from non-small cell lung cancer promotes tumor metastasis through the inhibition of HIPK2. Cell Death Dis, 2021; 12(8):747; doi: 10.1038/s41419-021-04024-9
30.
LiL, YuAQ. The functional role of peroxiredoxin 3 in reactive oxygen species, apoptosis, and chemoresistance of cancer cells. J Cancer Res Clin Oncol, 2015; 141(12):2071–2077; doi: 10.1007/s00432-015-1916-3
31.
LiuDR, GuanQL, GaoMT, et al.miR-1260b is a Potential Prognostic Biomarker in Colorectal Cancer. Med Sci Monit, 2016; 22:2417–2423; doi: 10.12659/msm.898733
32.
LiuJ, SunL, ChenD, et al.Prdx6-induced inhibition of ferroptosis in epithelial cells contributes to liquiritin-exerted alleviation of colitis. Food Funct, 2022; 13(18):9470–9480; doi: 10.1039/d2fo00945e
MirzaeiR, ZamaniF, HajibabaM, et al.The pathogenic, therapeutic and diagnostic role of exosomal microRNA in the autoimmune diseases. J Neuroimmunol, 2021; 358:577640; doi: 10.1016/j.jneuroim.2021.577640
35.
NonnL, BerggrenM, PowisG. Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol Cancer Res, 2003; 1(9):682–689.
36.
NovakEA, MollenKP. Mitochondrial dysfunction in inflammatory bowel disease. Front Cell Dev Biol, 2015; 3:62; doi: 10.3389/fcell.2015.00062
37.
OrlandoRC. Mechanisms of epithelial injury and inflammation in gastrointestinal diseases. Rev Gastroenterol Disord, 2002;2(Suppl 2):S2–S8. 12478238.
38.
PapoutsopoulouS, BurkittMD, BergeyF, et al.Macrophage-specific NF-κB activation dynamics can segregate inflammatory bowel disease patients. Front Immunol, 2019; 10:2168; doi: 10.3389/fimmu.2019.02168
39.
ParkEJ, ShimaokaM, KiyonoH. Functional flexibility of exosomes and MicroRNAs of intestinal epithelial cells in affecting inflammation. Front Mol Biosci, 2022; 9:854487; doi: 10.3389/fmolb.2022.854487
40.
Piechota-PolanczykA, FichnaJ. Review article: The role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases. Naunyn-Schmiedeberg’s Arch Pharmacol, 2014; 387(7):605–620; doi: 10.1007/s00210-014-0985,
41.
PorrasA, ZuluagaS, BlackE, et al.P38 alpha mitogen-activated protein kinase sensitizes cells to apoptosis induced by different stimuli. Mol Biol Cell, 2004; 15(2):922–933; doi: 10.1091/mbc.e03-08-0592
42.
QiH, WangY, FaS, et al.Extracellular vesicles as natural delivery carriers regulate oxidative stress under pathological conditions. Front Bioeng Biotechnol, 2021; 9:752019; doi: 10.3389/fbioe.2021.752019
43.
QuinlanAR, HallIM. BEDTools: A flexible suite of utilities for comparing genomic features. Bioinformatics, 2010; 26(6):841–842; doi: 10.1093/bioinformatics/btq033
44.
RaoR. Oxidative stress-induced disruption of epithelial and endothelial tight junctions. Front Biosci, 2008; 13:7210–7226; doi: 10.2741/3223
45.
RathE, MoschettaA, HallerD. Mitochondrial function—gatekeeper of intestinal epithelial cell homeostasis. Nature Reviews.Gastroenterology and Hepatology, 2018; 15(8):497–516.
46.
RodenburgW, KeijerJ, KramerE, et al.Impaired barrier function by dietary fructo-oligosaccharides (FOS) in rats is accompanied by increased colonic mitochondrial gene expression. BMC Genomics, 2008; 9:144; doi: 10.1186/1471-2164-9-144
47.
RoglerG, BrandK, VoglD, et al.Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology, 1998; 115(2):357–369; doi: 10.1016/s0016-5085(98)70202-1
48.
RupaimooleR, SlackFJ. MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov, 2017; 16(3):203–222; doi: 10.1038/nrd.2016.246
49.
SongIS, JeongYJ, JeongSH, et al.FOXM1-Induced PRX3 regulates stemness and survival of colon cancer cells via maintenance of mitochondrial function. Gastroenterology, 2015; 149(4):1006–1016.e9; doi: 10.1053/j.gastro.2015.06.007
50.
SonnSK, SongEJ, SeoS, et al.Peroxiredoxin 3 deficiency induces cardiac hypertrophy and dysfunction by impaired mitochondrial quality control. Redox Biol, 2022; 51:102275; doi: 10.1016/j.redox.2022.102275
51.
SorooshA, KoutsioumpaM, PothoulakisC, et al.Functional role and therapeutic targeting of microRNAs in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol, 2018; 314(2):G256–G262; doi: 10.1152/ajpgi.00268.2017
52.
TakagiT, HommaT, FujiiJ, et al.Elevated ER stress exacerbates dextran sulfate sodium-induced colitis in PRDX4-knockout mice. Free Radic Biol Med, 2019; 134:153–164; doi: 10.1016/j.freeradbiomed.2018.12.024
53.
TianT, WangZ, ZhangJ. Pathomechanisms of oxidative stress in inflammatory bowel disease and potential antioxidant therapies. Oxid Med Cell Longev, 2017; 2017:4535194; doi: 10.1155/2017/4535194
54.
WigginsJF, RuffinoL, KelnarK, et al.Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res, 2010; 70(14):5923–5930; doi: 10.1158/0008-5472.CAN-10-0655
55.
WonHY, JangEJ, LeeK, et al.Ablation of peroxiredoxin II attenuates experimental colitis by increasing FoxO1-induced Foxp3+ regulatory T cells. J Immunol, 2013; 191(8):4029–4037; doi: 10.4049/jimmunol.1203247
56.
WuN, DuX, PengZ, et al.Silencing of peroxiredoxin 1 expression ameliorates ulcerative colitis in a rat model. J Int Med Res, 2021; 49(3):300060520986313; doi: 10.1177/0300060520986313
57.
WuM, WangM, JiaH, et al.Extracellular vesicles: Emerging anti-cancer drugs and advanced functionalization platforms for cancer therapy. Drug Deliv, 2022; 29(1):2513–2538; doi: 10.1080/10717544.2022.2104404
58.
XiaS, XuC, LiuF, et al.Development of microRNA-based therapeutics for central nervous system diseases. Eur J Pharmacol, 2023; 956:175956; doi: 10.1016/j.ejphar.2023.175956
59.
ZhangW, LiuR, ChenY, et al.Crosstalk between oxidative stress and exosomes. Oxid Med Cell Longev, 2022; 2022:3553617; doi: 10.1155/2022/3553617
60.
ZhouJ, LiuJ, GaoY, et al.miRNA-Based Potential Biomarkers And New Molecular Insights In Ulcerative Colitis. Front Pharmacol, 2021; 12:707776; doi: 10.3389/fphar.2021.707776
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
